- Home
- CRGX vs DC Comparison
CRGX vs DC Comparison
Compare CRGX & DC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- DC
- Stock Information
- Founded
- CRGX 2021
- DC 2017
- Country
- CRGX United States
- DC United States
- Employees
- CRGX N/A
- DC N/A
- Industry
- CRGX
- DC Precious Metals
- Sector
- CRGX
- DC Basic Materials
- Exchange
- CRGX Nasdaq
- DC Nasdaq
- Market Cap
- CRGX 213.5M
- DC 209.6M
- IPO Year
- CRGX 2023
- DC N/A
- Fundamental
- Price
- CRGX $4.02
- DC $3.10
- Analyst Decision
- CRGX Hold
- DC Buy
- Analyst Count
- CRGX 7
- DC 1
- Target Price
- CRGX $4.67
- DC $7.50
- AVG Volume (30 Days)
- CRGX 763.5K
- DC 465.7K
- Earning Date
- CRGX 05-16-2025
- DC 05-08-2025
- Dividend Yield
- CRGX N/A
- DC N/A
- EPS Growth
- CRGX N/A
- DC N/A
- EPS
- CRGX N/A
- DC N/A
- Revenue
- CRGX N/A
- DC N/A
- Revenue This Year
- CRGX $58.18
- DC N/A
- Revenue Next Year
- CRGX N/A
- DC N/A
- P/E Ratio
- CRGX N/A
- DC N/A
- Revenue Growth
- CRGX N/A
- DC N/A
- 52 Week Low
- CRGX $3.00
- DC $1.84
- 52 Week High
- CRGX $25.45
- DC $3.50
- Technical
- Relative Strength Index (RSI)
- CRGX 37.02
- DC 68.16
- Support Level
- CRGX $3.97
- DC $2.71
- Resistance Level
- CRGX $4.66
- DC $2.84
- Average True Range (ATR)
- CRGX 0.20
- DC 0.12
- MACD
- CRGX -0.05
- DC 0.03
- Stochastic Oscillator
- CRGX 6.25
- DC 100.00
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine.